Pricing
Honest tiers grounded in the real unit economics of a feasibility run. CROs run on a platform plan — volume, white-label, dedicated-cluster, PO/invoice. Biotech and academic teams start per-study. No per-seat pricing.
Per-study, annual, and CRO platform tiers.
For CROs & large sponsors
Volume pricing scoped to your bid pipeline
For CROs running feasibility across many sponsors and protocols. Resell cited verdicts under your own brand, run in a dedicated single-tenant cluster, and screen whole portfolios ahead of the bid.
For biotech & academic teams
For low-volume and academic teams running the occasional feasibility check. Pay for the protocols you actually analyse — nothing else.
For a biotech running feasibility as a regular part of trial planning. Roughly twelve analyses a year at a predictable annual rate.
For teams that want feasibility on tap across a growing pipeline — run as many protocols as you need without metering each one.
At a glance
| Plan | Per-study | Biotech Starter | Biotech Pro |
|---|---|---|---|
| Best for | The occasional check | About a protocol a month | A growing pipeline |
| Price | $2,500–$8,000 | ~$28k | ~$65k |
| Billed | Per protocol | Per year | Per year |
| Assessments | One per protocol | ~12 per year | High volume (fair use) |
| Payment | Card | PO or invoice | PO or invoice |
No per-seat pricing. CROs and larger sponsors run on the CRO Platform plan — white-label, dedicated-cluster, and PO/invoice billing. Annual and platform plans support purchase-order and invoice payment; per-study runs can be paid by card.
A few honest notes
If you are an early biotech willing to run real protocols and tell us where the verdict is wrong, the per-study range bends toward the bottom — and your feedback shapes the roadmap.
Biotech Starter assumes about a protocol a month; Biotech Pro removes the meter entirely for teams analysing across a pipeline. If your volume sits between them, we will quote the honest middle rather than push you up a tier.
Final numbers depend on indication complexity, analysis depth, and deployment model. We would rather scope it with you than hide it behind a sales motion.
Tell us your indication, volume, and deployment model. We'll come back with an honest, itemised quote and a sample cited verdict — not a sales sequence.